Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Frankfurt – page 107

1 491 clinical trials in Frankfurt, Germany across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Frankfurt at a glance
1 491
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

1 491 trials in Frankfurt

Open in trial search

Actinic keratosis

Not recruiting

Study on the Safety of Tirbanibulin and Diclofenac Sodium for Adults with Actinic Keratosis on the Face or Scalp

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac Sodium
  • Sponsor:Almirall S.A.

Diffuse large B-cell lymphoma+2

Not recruiting

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Celgene Corp.

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Age-related macular degeneration

Not recruiting

Study on the Effectiveness and Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a 36-Week Refill System

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Psoriasis

Not recruiting

Study on Bimekizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Short stature+3

Not recruiting

Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Hereditary angioedema with C1 esterase inhibitor deficiency

Not recruiting

Study on Deucrictibant and Icatibant for Treating Hereditary Angioedema Attacks in Adolescents and Adults

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Glioblastoma

Not recruiting

Study of Troriluzole and ADI-PEG-20 for Patients with Newly Diagnosed and Recurrent Glioblastoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elrelesertib
  • Sponsor:Global Coalition For Adaptive Research Inc.

Non-small cell lung cancer

Not recruiting

Study of Sacituzumab Govitecan, Pembrolizumab, and a Platinum Drug Combination for Advanced Non-Small Cell Lung Cancer Patients Without Genomic Alterations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Celgene Corp.

Gastrooesophageal cancer

Not recruiting

Study on Regorafenib and Nivolumab for Patients with Advanced Gastro-Oesophageal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Frankfurt

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on hematologic malignancies and solid tumors, including innovative treatments for lymphoma, leukemia, and various gastrointestinal cancers.

  • Chronic Lymphocytic Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Gastric Cancer
  • Pancreatic Cancer

Studies evaluate novel therapeutic combinations and targeted treatments to improve patient outcomes.

02 Gastrointestinal Disorders

Research initiatives examining treatments for inflammatory bowel conditions, including Crohn's Disease and Ulcerative Colitis, with emphasis on long-term management approaches.

  • Moderate to Severe UC
  • Active Crohn's Disease
  • GI Tract Infections

Focus on innovative therapeutic options for chronic inflammatory conditions.

03 Rare Diseases

Clinical investigations of treatments for rare conditions, including Von Willebrand Disease and Dravet Syndrome, exploring novel therapeutic approaches.

  • Blood Disorders
  • Genetic Conditions
  • Neurological Disorders

Development of targeted therapies for previously difficult-to-treat conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.